XenoPort, Inc. - We are a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. In April 2011, the FDA approved our first product, Horizant™ (gabapentin enacarbil) Extended-Release Tablets. Our collaborator, GlaxoSmithKline (GSK), is currently promoting Horizant in the United States. We are also developing gabapentin enacarbil with Astellas Pharma Inc. in Japan and five Asian countries. XenoPort’s product candidates are being developed for the potential treatment of neuropathic pain, spasticity and Parkinson’s disease.

For more information, please click here

Tue, 14 Feb 2012 XenoPort Reports Fourth Quarter and Year-End 2011 Financial Results Fri, 10 Feb 2012 XenoPort to Present at the Leerink Swann Global Healthcare Conference   XenoPort, Inc. at Leerink Swann Global Healthcare Conference Thursday, February 16, 2012 10:30 a.m. PT Q4 2011 XenoPort, Inc. Earnings Conference Call Tuesday, February 14, 2012 5:00 p.m. ET

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including neuropathic pain, spasticity and Parkinson’s disease. Explore the XenoPort Pipeline >